small molecule

KYGEVVI

DOXECITINE; DOXRIBTIMINE

Loss of exclusivityAugust 2040latest FDA-listed patent expiry

CompanyUCB →See this company's full patent-cliff portfolio

Drug detail

Brand name	KYGEVVI
Active ingredient	DOXECITINE; DOXRIBTIMINE
Strength	2GM/PACKET;2GM/PACKET
Dosage form	FOR SOLUTION
Route	ORAL
Modality	Small molecule
FDA approval	November 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
11649259	August 2040	product
10471087	August 2036	use U-4358

Regulatory exclusivity

Code	Expires
NCE	November 2030

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from UCB